Histological reactivity of a monoclonal antibody against rat colon cancer cells on human and rat normal gut and colonic tumours

1992 ◽  
Vol 420 (3) ◽  
pp. 233-242 ◽  
Author(s):  
P. Genne ◽  
N. -O. Olsson ◽  
A. Caignard ◽  
R. Oriol ◽  
J. Bara ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Colon Cancer ◽  
Cancer Cells ◽  
Rat Colon ◽  
Colon Cancer Cells ◽  
Colonic Tumours

scholarly journals Deacetylase Plus Bromodomain Inhibition Downregulates ERCC2 and Suppresses the Growth of Metastatic Colon Cancer Cells

Cancers ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 1438
Author(s):  
Sabeeta Kapoor ◽  
Trace Gustafson ◽  
Mutian Zhang ◽  
Ying-Shiuan Chen ◽  
Jia Li ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Cancer Cells ◽  
Excision Repair ◽  
Critical Role ◽  
Rat Colon ◽  
Precision Oncology ◽  
Metastatic Colon Cancer ◽  
Colon Cancer Cells ◽  
Combination Drug ◽  
Human Colon Cancer

There is growing evidence that DNA repair factors have clinical value for cancer treatment. Nucleotide excision repair (NER) proteins, including excision repair cross-complementation group 2 (ERCC2), play a critical role in maintaining genome integrity. Here, we examined ERCC2 expression following epigenetic combination drug treatment. Attention was drawn to ERCC2 for three reasons. First, from online databases, colorectal cancer (CRC) patients exhibited significantly reduced survival when ERCC2 was overexpressed in colon tumors. Second, ERCC2 was the most highly downregulated RNA transcript in human colon cancer cells and rat tumors after treatment with the histone deacetylase 3 (HDAC3) inhibitor sulforaphane (SFN) plus JQ1, which is an inhibitor of the bromodomain and extraterminal domain (BET) family. Third, as reported here, RNA-sequencing of polyposis in rat colon (Pirc) polyps following treatment of rats with JQ1 plus 6-methylsulfinylhexyl isothiocyanate (6-SFN) identified Ercc2 as the most highly downregulated gene. The current work also defined promising second-generation epigenetic drug combinations with enhanced synergy and efficacy, especially in metastasis-lineage colon cancer cells cultured as 3D spheroids and xenografts. This investigation adds to the growing interest in combination approaches that target epigenetic ‘readers’, ‘writers’, and ‘erasers’ that are deregulated in cancer and other pathologies, providing new avenues for precision oncology and cancer interception.

Effect of AbGn-7, a glycotope-specific monoclonal antibody, on apoptosis in colon cancer cells and tumor growth in xenograft models

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e15118-e15118
Author(s):  
S. Lin ◽  
E. Chiang ◽  
Y. Tsai ◽  
S. Lee ◽  
B. Kuo ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Monoclonal Antibody ◽  
Colon Cancer ◽  
Monoclonal Antibodies ◽  
Cancer Cells ◽  
Parp Cleavage ◽  
Potential Candidate ◽  
Dependent Manner ◽  
Colon Cancer Cells ◽  
Dose Dependent

e15118 Background: While clinical benefit against colorectal cancer has been observed with therapeutic monoclonal antibodies such as bevacizumab, cetuximab and panituzumab, the death rate of advanced colorectal cancer remains high that warrants further development of more potent therapeutics. Methods: A cell-based immunization approach was used to generate monoclonal antibodies against targets expressed on human colorectal cancer cells. A chimeric monoclonal antibody, AbGn-7, was selected and evaluated for the potential clinical use to treat colorectal cancer. Results: Expression of AbGn-7 antigen: Carbohydrate competition assay demonstrated that AbGn-7 recognizes a Lewis-A-like carbohydrate antigen (AbGn-7 antigen). Immunohistochemical studies showed that AbGn-7 antigen is expressed in colorectal cancer tissue. No significant binding could be detected in non-tumor tissues except in the epithelia of GI track. Effector function of AbGn-7: AbGn-7 triggered dose-dependent apoptosis in COLO 205 colon cancer cell. In addition, AbGn-7 elicited potent complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) in a dose-dependent manner. Molecular mechanism of apoptosis induced by AbGn-7: Tunel assay, PARP cleavage assay as well as caspase inhibitor studies demonstrated that AbGn-7 induced apoptosis in COLO 205 colon cancer cells via a caspase-independent pathway. Xenograft study: AbGn-7 alone, or in combination with 5FU-Leucovorin, effectively inhibited the growth of COLO 205 xenograft in SCID mice and prolonged their survival. Conclusions: The results of the present study suggest that AbGn-7 is a potential candidate for effective treatment of colorectal cancer. [Table: see text]

A novel apoptosis-inducing monoclonal antibody (anti-LHK) against a cell surface antigen on colon cancer cells

2005 ◽  
Vol 40 (10) ◽  
pp. 945-955 ◽  
Author(s):  
Hidehiko Matsukawa ◽  
Takanori Kanai ◽  
Makoto Naganuma ◽  
Nobuhiko Kamada ◽  
Tadakazu Hisamatsu ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Colon Cancer ◽  
Cell Surface ◽  
Cancer Cells ◽  
Surface Antigen ◽  
Cell Surface Antigen ◽  
Colon Cancer Cells ◽  
A Cell

Human monoclonal antibody SK1-mediated cytotoxicity against colon cancer cells

1993 ◽  
Vol 36 (12) ◽  
pp. 1152-1157 ◽  
Author(s):  
Helena R. Chang ◽  
Bahman Chavoshan ◽  
Henry Park
Keyword(s):  
Monoclonal Antibody ◽  
Colon Cancer ◽  
Cancer Cells ◽  
Human Monoclonal Antibody ◽  
Colon Cancer Cells

Effects of fatty acids on liver metastasis of ACL‐15 rat colon cancer cells

1998 ◽  
Vol 31 (2) ◽  
pp. 143-150 ◽  
Author(s):  
Shigeyoshi Iwamoto ◽  
Hideto Senzaki ◽  
Yasuhiko Kiyozuka ◽  
Eliko Ogura ◽  
Hideho Takada ◽  
...  
Keyword(s):  
Fatty Acids ◽  
Colon Cancer ◽  
Liver Metastasis ◽  
Cancer Cells ◽  
Rat Colon ◽  
Colon Cancer Cells
Sign in / Sign up

Export Citation Format

Share Document